Gene: ENSA

2029
ARPP-19e
endosulfine alpha
protein-coding
1q21.3
Ensembl:ENSG00000143420 MIM:603061 Vega:OTTHUMG00000035004 UniprotKB:O43768
NG_029499.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.315e-1 (AD)  6.035e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KLC10.944
BCL2L20.936
RTN40.929
DYNLL20.926
ARPP190.925
TRUB20.922
HABP40.919
ATP6V1G20.917
TCEAL70.917
FAM219A0.916

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.705
OR4F5-0.684
EVC2-0.385
RNF135-0.381
CXCR2-0.378
CDC14A-0.377
FCGR3B-0.375
TGIF1-0.373
RREB1-0.37
MAGEA12-0.365

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of ENSA mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of ENSA mRNA21420995
D000082Acetaminophen[Clofibrate co-treated with Acetaminophen] affects the expression of ENSA mRNA17585979
D000082AcetaminophenPPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of ENSA mRNA]17585979
D000643Ammonium ChlorideAmmonium Chloride affects the expression of ENSA mRNA16483693
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of ENSA mRNA22228805
D004958EstradiolEstradiol results in decreased expression of ENSA mRNA23019147
C006780bisphenol Abisphenol A results in decreased expression of ENSA mRNA25181051
D002737ChloropreneChloroprene results in increased expression of ENSA mRNA23125180
D002994Clofibrate[Clofibrate co-treated with Acetaminophen] affects the expression of ENSA mRNA17585979
D002994ClofibratePPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of ENSA mRNA]17585979
C018021cobaltous chloridecobaltous chloride results in decreased expression of ENSA mRNA19376846
C014347decitabinedecitabine affects the expression of ENSA mRNA23300844
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of ENSA mRNA21266533
D002945CisplatinCisplatin affects the expression of ENSA mRNA23300844
D002945CisplatinCisplatin results in increased expression of ENSA mRNA27594783
D002945CisplatinCisplatin results in increased phosphorylation of ENSA protein22006019
C118739entinostatentinostat results in decreased expression of ENSA mRNA27188386
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of ENSA mRNA23649840
C492448ICG 001ICG 001 results in decreased expression of ENSA mRNA26191083
C410337K 7174K 7174 results in increased expression of ENSA mRNA24086573
D007854LeadLead affects the expression of ENSA mRNA28903495
C042720mercuric bromidemercuric bromide results in increased expression of ENSA mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of ENSA mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of ENSA mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of ENSA mRNA"20188158
C583365N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide"N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in decreased expression of ENSA mRNA"29244179
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of ENSA mRNA"25554681
C025589ochratoxin Aochratoxin A results in decreased expression of ENSA mRNA22124623
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of ENSA mRNA26272509
C006253pirinixic acidpirinixic acid results in increased expression of ENSA mRNA17426115
C045950propiconazolepropiconazole results in decreased expression of ENSA mRNA21278054
C017947sodium arsenitesodium arsenite results in increased expression of ENSA mRNA28595984
C041711St. Thomas' Hospital cardioplegic solutionSt. Thomas' Hospital cardioplegic solution results in increased expression of ENSA mRNA16214533
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ENSA mRNA21570461
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENSA mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ENSA mRNA23179753|2597931
D014635Valproic AcidValproic Acid results in decreased expression of ENSA mRNA27188386
D014635Valproic AcidValproic Acid results in increased expression of ENSA mRNA24383497|2627250
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of ENSA gene25560391
C025643vinclozolinvinclozolin affects the expression of ENSA mRNA19015723
C025643vinclozolinvinclozolin results in increased expression of ENSA mRNA23034163
D014750VincristineVincristine results in decreased expression of ENSA mRNA23649840

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004864protein phosphatase inhibitor activity-IBA21873635  
GO:0005102signaling receptor binding-IDA9653196  
GO:0005515protein binding-IPI21044950  
GO:0008200ion channel inhibitor activity-TAS9653196  
GO:0019212phosphatase inhibitor activity-ISS-  
GO:0019870potassium channel inhibitor activity-IDA9653196  
GO:0019888protein phosphatase regulator activity-ISS-  
GO:0051721protein phosphatase 2A binding-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000086G2/M transition of mitotic cell cycle-ISS-  
GO:0000278mitotic cell cycle-ISS-  
GO:0007584response to nutrient-TAS9653196  
GO:0009749response to glucose-IEA-  
GO:0032515negative regulation of phosphoprotein phosphatase activity-IEA-  
GO:0035308negative regulation of protein dephosphorylation-IBA21873635  
GO:0050796regulation of insulin secretion-IDA9653196  
GO:0051301cell division-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1640170Cell CycleTAS
R-HSA-1640170Cell CycleIEA
R-HSA-2465910MASTL Facilitates Mitotic ProgressionTAS
R-HSA-2465910MASTL Facilitates Mitotic ProgressionIEA
R-HSA-68875Mitotic ProphaseTAS
R-HSA-68875Mitotic ProphaseIEA
R-HSA-68886M PhaseTAS
R-HSA-68886M PhaseIEA
R-HSA-69278Cell Cycle, MitoticTAS
R-HSA-69278Cell Cycle, MitoticIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
12820496[Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Final outcomes from the National Health Survey 2000]. (2003 Jan-Mar)Velazquez-Monroy OArch Cardiol Mex